Navigation Links
Clinical Symptoms Enough to Switch Drug Regimens for HIV Patients
Date:4/24/2008

Study showed little difference in survival when compared to expensive lab tests

THURSDAY, April 24 (HealthDay News) -- Decisions on switching to a second-line series of drugs for HIV/AIDS patients who are failing the first-line regimen are often made on the basis of sophisticated and expensive lab tests.

But a new study shows that survival is only slightly affected if these decisions are based instead on the appearance of clinical symptoms.

Researchers still need to develop less expensive versions of laboratory tests currently used, but lack of test availability shouldn't affect access to highly effective drugs in poorer nations, said the authors of a study in this week's issue of The Lancet.

"I hope that the findings will reassure health policy makers and clinicians that they should continue to make every effort to widen access to ART and not allow any concerns over lack of laboratory monitoring to inhibit this," said study author Andrew Phillips, a professor of epidemiology at Royal Free and University Medical School in London.

The World Health Organization (WHO) recommends that, in lower-income areas, decisions regarding drug treatment for HIV be based on symptoms and, when available, CD4 cell count, rather than viral load.

With viral load, switches to second-line treatment occur when the viral load exceeds 500 copies per millileter.

CD4 cells are a type of immune system cell. Patients generally switch to the second-line drugs when CD4 counts in the blood drop 50 percent from their highest.

WHO-recommended first-line treatment consists of the antiretroviral drugs Zerit (stavudine), Epivir (lamivudine) and Viramune (nevirapine).

Using a computer simulation model to analyze how antiretroviral therapy influences HIV infection, the researchers compared survival rates, switch of second-line medication regimens and development of resistance for three different strategies: monitoring viral load and CD4 cell count or clinical observation.

Over a period of five years, 83 percent of patients using the viral load monitoring strategy, 82 percent using CD4 cell count monitoring, and 82 percent using clinical monitoring survived.

After a period of 20 years, survival rates were 67 percent, 64 percent and 64 percent, respectively. Viral load monitoring showed a slightly longer survival but was not the most cost-effective avenue (at a cost of around $3,500 per life-year gained).

Other experts were concerned that the results might be construed to mean viral load monitoring and CD4 cell count should be abandoned in the developed world.

"It's a great study, but it has no application to First World countries," said Dr. Michael Horberg, director of HIV/AIDS policy at Kaiser Permanente Health Plan in Santa Clara, Calif. "There is wide availability of these tests, and there should be funds to support such monitoring.

"Having said that, it has to be well-acknowledged that in resource-limited nations, CD4 count and viral load monitoring are expensive and have limited availability, and clinical decisions have to be made on the basis of clinical impressions," Horberg continued. "Health-care infrastructures must be sent to resource-limited nations. However, in the interim, clinicians should at least be reassured that their clinical practices are not doing undue harm.

"Infectivity seems to be increased with increased viral load. Not monitoring viral load could mean that highly infectious patients are passing the virus to new people and, indeed, a virus which is already resistant to drugs."

More information

The World Health Organization has more on antiretroviral therapy for HIV infection.



SOURCES: Andrew N. Phillips, Ph.D., professor, epidemiology, Royal Free and University Medical School, London; Michael Horberg, M.D., director, HIV/AIDS policy, Kaiser Permanente Health Plan, Santa Clara, Calif.; April 26, 2008, The Lancet


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Cancer researchers receive NIH grant to advance brain tumor therapies from lab to clinical trials
2. Versus Technology, Inc. Announces Collaboration with Cleveland Clinic to Create Clinical Patient Flow Model
3. Welchol(TM) Added to the American College of Endocrinology/American Association of Clinical Endocrinologists Road Maps to Achieve Glycemic Control in Patients with Type 2 Diabetes Mellitus
4. Precyse Solutions Launches Clinical Documentation Improvement Program to Assist Hospitals in Accelerating Revenues
5. Clinical guidelines for the manual titration of PAP in OSA patients published in JCSM
6. Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
7. Siemens New Clinical Education Training Facility Opens Doors and Expands Offerings for Imaging Professionals
8. Allegro Diagnostics Announces Publication in Cancer Prevention Research of Prediction Model for Lung Cancer Diagnosis Integrating Clinical and Genomic Features
9. Clinical Trial Volunteers Uneasy About Some Financial Ties
10. Quintiles Ranks First in Pan-European Clinical Investigator Study
11. Rejuvasun(TM) With Omnilux(TM): Industry First to Feature FDA-Cleared, Clinically Proven Light Therapy Technology
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Clinical Symptoms Enough to Switch Drug Regimens for HIV Patients
(Date:3/24/2017)... ... ... Digital Scientists, a software innovation lab specializing in web design and ... Carolina location. The lab has set up shop at the renowned NEXT Innovation ... Carolina clients for years from our office here in Atlanta,” explains Digital Scientists’ CEO, ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... planning, and related services to families and business owners across eastern Michigan, is ... feeding regional families struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry ...
(Date:3/24/2017)... ... 2017 , ... On June 9, 2017, Cassie Springer Ayeni ... in Chicago, Illinois. She will present on: , Filing Benefit Claims—Responding to ... involve claims for long-term disability benefits. This session will address the first ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... first Certified Medical Reiki™ Master in Frederick, MD. Judy says, “I am passionate ... during what is often a very difficult and challenging time.” , A Certified ...
(Date:3/24/2017)... ... 24, 2017 , ... “The Adventures of Joey, The Dog Who Barks at ... his life to the fullest, as God intended. “The Adventures of Joey, The Dog ... and grandmother pursuing her passion for writing, especially about truth and human behavior. , ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global Idiopathic ... ... strong with a total of 97 drug candidates. Pharma giant such as ... in the development of the IPF therapeutics. The IPF pipeline comprised of ... are in Phase II stage, 12 are in Phase I stage, 39 ...
(Date:3/24/2017)... DUBLIN , Mar 24, 2017 Research ... Supplies - Global Strategic Business Report" report to their offering. ... The report provides separate comprehensive ... , Europe , Asia-Pacific , ... and forecasts are provided for the period 2015 through 2022. Also, a ...
(Date:3/24/2017)... 23, 2017  Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... clinical-stage oncology and dermatology biopharmaceutical company, today disclosed ... Term Sheet (the "Definitive Financing") it entered into ... Company,s stockholders, who are referred to in the ... 8-K filed with the Securities and Exchange Commission. ...
Breaking Medicine Technology: